Drugs / PANHPVAX
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05208710 | Nov 2022 → Dec 2027 expected | human papilloma virus infection | German Cancer Research Center | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PANHPVAX | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05208710 ↗ |
| Modality | Vaccine | “PANHPVAX, a vaccine against human papilloma L2 antigens formulated with cdA (adjuvant)” NCT05208710 ↗ |
| Route | Intramuscular | “with an intramuscular (i.m.) prime and two i.m. booster injections” NCT05208710 ↗ |